zurück

Upadacitinib (new indication: atopic dermatitis, patients aged ≥ 12 years)

Subject:

  • Active Substance: Upadacitinib
  • Name: Rinvoq®
  • Therapeutic area: Atopic dermatitis
  • Pharmaceutical company: AbbVie Deutschland GmbH & Co. KG

Time table:

  • Start: 01.09.2021
  • Final decision by G-BA: 17.02.2022

Final decision:

  • Adult patients for which 30 mg upadacitinib is the appropriate dosage:
    - Indication for a considerable additional benefit
  • Adult patients for which 15 mg upadacitinib is the appropriate dosage:
    - No additional benefit proved
  • Adolescents of 12 - < 18 years of age:
    - No additional benefit proved